Navigation Links
Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements
Date:9/17/2008

Nine out of 10 ENDOMETRIN users would recommend it to a friend

PARSIPPANY, N.J., Sept. 17 /PRNewswire/ -- Results of a nationwide survey of infertility patients undergoing an assisted reproductive technology treatment (ART), such as in vitro fertilization, revealed that patients prefer ENDOMETRIN(R) (progesterone) Vaginal Inserts to progesterone-in-oil (PIO) injections, and to all other vaginal progesterone supplements. The reasons cited most frequently for their preference included easy, convenient and pain-free administration.

Adequate progesterone support is considered extremely important for a successful pregnancy. Since natural progesterone production may be compromised by ART, progesterone supplements are used extensively for luteal phase and early pregnancy support. There are several forms: oral, injection, and vaginal -- tablet inserts, vaginal capsules, suppositories and gels.

"The survey confirms what we hear all the time from patients -- that when they reach the final stage of their IVF treatment, the last thing they want is another series of shots or inconvenient treatments," said Christine Stroup, RN. "Our patients are very pleased with ENDOMETRIN because it's simple to use and very convenient."

"I've tried just about every progesterone treatment available, and was so happy to find one that didn't hurt, like shots, and wasn't messy, like gels and suppositories," said Victoria Knapp, IVF patient. "After all those cycles of treatment I went through, it was a relief to find one that was so simple to use."

The Evaluation of Attitudes and Satisfaction with Endometrin Survey of 212 patients was commissioned by Ferring Pharmaceuticals Inc. to compare patient satisfaction with ENDOMETRIN, the most recent progesterone supplement to enter the market, with all other progesterone supplements.

Key Survey Findings

-- More than 90 percent of patients would recommend ENDOMETRIN to a friend

undergoing infertility treatment, 84 percent would request it for their

next treatment cycle, and 93 percent found the dosing regimen easy to

fit into their daily routine. When asked to describe it in three words,

the most common were: "easy, convenient, painless and

comfortable."

-- The vast majority found the vaginal inserts more convenient (87

percent), comfortable (89 percent), and easier to administer (95

percent) compared with injections, taken by 154 respondents. Of the

women who needed a partner to administer the shots, most (65 percent)

said their partner felt anxious about it.

-- Of the 62 women who used the capsules administered vaginally, most said

ENDOMETRIN was more convenient (74 percent), comfortable (nearly 70

percent), and easier to administer (83 percent).

-- Patients found suppositories, made by the pharmacy, awkward to

administer without an applicator. Of the 83 women who used them, nearly

90 percent said they melted or leaked, and more than half said they

caused irritation.

-- Nearly 80 percent of the 26 gel users said gel created build-up, nearly

50 percent found gel messy to administer and more than one-third said it

caused irritation.

-- While 20 of the 40 women who used the oral form preferred the

administration convenience of ENDOMETRIN and 13 preferred the oral

supplement, the oral form is widely considered less effective than other

options.

Methodology

Nurses at more than 60 designated fertility centers across the country selected qualified patients who had used or were about to start ENDOMETRIN in an IVF or ovulation induction cycle. Patients must also have used a different progesterone supplement in a previous or current cycle. The survey reflects the patient's most recent treatment cycle. The majority of the 212 patients were 40-years-old or younger; nearly 40 percent had been in fertility treatment for more than two years.

About ENDOMETRIN

ENDOMETRIN administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to two percent included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than two percent. ENDOMETRIN is expected to have adverse reactions to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness).

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets MENOPUR(R) (menotropins for injection, USP), BRAVELLE(R) (urofollitropin for injection, purified), REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN in the U.S. to infertility specialists and their patients. Ferring also offers the Q?CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(R) (1% sodium hyaluronate) hyaluronic acid for pain from osteoarthritis in the knee and PROSED(R)/DS for the relief of discomfort of the lower urinary tract. Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit http://www.ferringusa.com or http://www.ferringfertility.com.

Contact Andrea Preston for full prescribing information for ENDOMETRIN.


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection
2. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
3. 10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide
4. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
5. Survey Shows Parents Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
8. The ED Conversation Dilemma: Forty Percent of Men with ED Dont Talk to Their Doctor, Survey Finds
9. As Summer Heats Up, New Survey Reveals Need for Effective Sweat Treatments
10. New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact
11. New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... capillary electrophoresis market to grow at a CAGR of 7.06% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:3/23/2017)... Newborns are highly vulnerable to infections ... their young immune systems typically mount weak antibody ... achieving strong vaccine responses in newborn animals, including ... trials — by adding compounds known as adjuvants ... papers, they also describe improved adjuvant formulations that ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... inspiring stories about real people of God in congregations across the United States. ... a Presbyterian minister ordained in 1964 who has served congregations in seven states ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... , ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth ... two times a day that dentists recommend. The ramifications of improper oral upkeep go far ... adults missing 164 million hours of work each year due to dental issues. That is ...
(Date:3/23/2017)... ... 23, 2017 , ... Hakim Unique Group (HUG) just closed ... Healthcom Group (CHG). , The HUG investment is a landmark move, expanding ... CHG is a growing, internationally recognized healthcare management, technology, and services organization. It ...
(Date:3/23/2017)... ... ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 backers ... crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, LLC, ... excited to be operating on U.S. shores, where most of our initial crowdfunding backers ...
Breaking Medicine News(10 mins):